Am J Transplant, Volume 19, Suppl 3 Archives - Page 14 of 214 - ATC Abstracts

2019 American Transplant Congress
Differences in the Cost of Recovering Organs over Time
J. P. Roberts¹, J. Bragg-Gresham², P. Held³
¹Univ of California-San Francisco, San Francisco, CA, ²Univ of Michigan, Ann Arbor, CA, ³Stanford University, Stanford, CA
*Purpose: To report on the level and changes over time in the OPOs’ cost of recovering deceased donor organs (kidneys; livers; hearts; and lungs).*Methods: Cost…
2019 American Transplant Congress
Donor Brain Death Affects Tolerance Induction in Non-Human Primates
W. Sommer¹, J. M. O², K. B. Pruner³, J. T. Paster³, A. Bean³, A. Dehnadi³, I. M. Hanekamp³, I. Rosales⁴, R. N. Smith⁴, R. B. Colvin⁴, G. Benichou³, J. S. Allan³, T. Kawai³, J. C. Madsen⁵
¹Department of Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, ²Center for Transplantation Sciences, Massachusets General Hospital, Boston, MA, ³Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ⁴Department of Pathology, Massachusetts General Hospital, Boston, MA, ⁵Center fro Transplantation Sciences, Massachusetts General Hospital, Boston, MA
*Purpose: Induction of durable allograft acceptance in combined heart/kidney transplantation in non-human primates is possible by applying a mixed chimerism-based conditioning protocol. However, the impact…
2019 American Transplant Congress
Acquired Resistance to Transplantation Tolerance as a Result of Prior Pregnancy Requires B Cells
D. V. Tran, A. N. Suah, S. Khiew, J. S. Young, Q. Wang, D. Yin, M. Alegre, A. S. Chong
Departments of Surgery and Medicine, University of Chicago, Chicago, IL
*Purpose: Clinical data suggest allogeneic pregnancy is a sensitizing event; however, data from mouse models suggests it induces fetal-specific regulatory T cell (Treg) expansion and…
2019 American Transplant Congress
Perioperative Cardiac Xenograft Dysfunction after Orthotopic Transplantation is for Real
M. Mohiuddin¹, A. Singh¹, L. DiChiacchio¹, D. Kaczorowski¹, B. Lewis¹, T. Zhang¹, F. Sentz¹, I. Tatarov¹, D. Parsell¹, P. Odonkor¹, E. Strauss¹, B. Williams¹, K. Deatrick¹, D. Ayares², B. Griffith¹, S. Bartlett¹
¹Department of Surgery, University of Maryland Baltimore, Baltimore, MD, ²Revivicor, Inc, Blacksburg, VA
*Purpose: After successful prolongation of cardiac xenograft survival in a heterotopic position, the next step is to evaluate genetically engineered (GE) pig hearts for their…
2019 American Transplant Congress
Recipient Myeloid Notch1 Disruption Shifts Neutrophil towards Anti-Inflammatory Phenotype and Protects Liver Grafts from Ischemia-Reperfusion Injury
S. Kageyama¹, H. Hirao¹, K. Kadono¹, K. Nakamura¹, K. J. Dery¹, T. Ito², D. Oncel¹, J. Aziz¹, B. Ke¹, F. M. Kaldas², R. W. Busuttil², J. W. Kupiec‐Weglinski¹
¹Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA, ²Surgery, Ronald Reagan UCLA Medical Center, UCLA, Los Angeles, CA
*Purpose: Liver ischemia-reperfusion injury (IRI) represents a major risk factor of early graft dysfunction and predisposes to rejection crises in orthotopic liver transplantation (OLT). We…
2019 American Transplant Congress
Bisphosphonates Effectively Improve the Long Term Renal Transplant Outcomes; A Single Center Retrospective Study
S. Song¹, K. Huh², H. Choi³, J. Lee², D. Kim², Y. Kim², M. Kim², S. Kim², D. Joo², B. Kim³
¹Surgery, Ewha Womans University, Seoul, Korea, Republic of, ²Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, ³Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
*Purpose: Kidney transplantation (KT) is a treatment of choice for patients with end-stage renal disease. Despite of remarkable improvement in short term graft survival, few…
2019 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962)
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamsons, C. Myers, K. Lim, J. Choi, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Currently, there is growing interest in development of novel immune-modulatory drugs likely to improve allo-antibody reduction in transplantation. Clazakizumab (Vitaeris Inc.) is a humanized…
2019 American Transplant Congress
Late Acute Rejection Increases Risk Of Graft Failure In Ldlt Recipients: Data From The A2all Cohort
H. J. Braun, J. L. Dodge, J. D. Grab, S. M. Syed, G. R. Roll, C. E. Freise, J. P. Roberts, N. L. Ascher
University of California, San Francisco, San Francisco, CA
*Purpose: Late acute rejection (LAR) is defined as an initial episode of acute rejection occurring >6 months after transplantation. LAR in liver transplantation (LT) is…
2019 American Transplant Congress
One Study: A Consortium Model of Clinical Trials Optimized for Comparing New Immune Therapies via Centralized Immune Monitoring
B. Sawitzki¹, S. Schlickeiser¹, M. Streitz¹, K. Jürchott¹, J. Hutchinson², E. Geissler², P. Investigators³
¹Charite Universitätsmedizin, Berlin, Germany, ²University of Regensburg, Regensburg, Germany, ³ONE Study Consortium, EU, Germany
*Purpose: Immune regulatory cell subpopulations can potentially control immune responses to allow immunosuppression (IS) drug minimization. In the ONE Study, an EU FP7-funded research group…
2019 American Transplant Congress
Prevention of Graft Ischemia-Reperfusion Injury in Ischemia-Free Liver Transplantation
Z. Guo, X. He, Q. Zhao, S. Huang, Z. Zhang, L. Wang, W. Ju, G. Chen
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
*Purpose: Graft ischemia-reperfusion injury (IRI) is an inevitable event in organ transplantation, which often leads to a number of complications and even patient deaths. We…